68Ga-DOTATATE Neuroblastoma Imaging Pilot
ConditionNeuroblastoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeUp to 21
SponsorCentre de recherche du Centre hospitalier universitaire de Sherbrooke
About this trial
Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.
Eligibility criteria
Qualifiers
Newly suspected or biopsy-proven neuroblastoma or recurrence of neuroblastoma
Planned 123I-MIBG imaging
Able and willing to provide signed informed consent in French or English (for the adult candidates or the parent/legal tutor of the pediatric candidates)
Aged between 1 day and 21 years old (inclusively).
Disqualifiers
History of another cancer in the past 5 years other than non-melanomatous skin cancer.
Currently under a randomized control trial with unknown allocation;
Currently under treatment;
Medical/surgical intervention on the tumour between 123I-MIBG and 68Ga-DOTATATE PET/CT scan.
Trial design
Treatments tested in this trial
- Radiopharmaceutical 68Ga-DOTATATE
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov